Noa G Holtzman, Lauren M Curtis, Rachel B Salit, Brian C Shaffer, Filip Pirsl, Alen Ostojic, Seth M Steinberg, Eduard Schulz, Jennifer S Wilder, Thomas E Hughes, Jeremy Rose, Sarfraz Memon, Robert Korngold, Juan Gea-Banacloche, Daniel H Fowler, Frances T Hakim, Ronald E Gress, Michael R Bishop, Steven Z Pavletic
Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplants (allo-HSCT). While in vivo lymphodepletion by antibodies for cGVHD prophylaxis has been explored in the myeloablative setting, its effects after reduced intensity conditioning (RIC) are not well described. Patients (n=83) with hematologic malignancies underwent targeted lymphodepletion chemotherapy followed by a RIC allo-HSCT using peripheral blood stem cells from unrelated donors...
April 26, 2024: Blood Advances